Abstract:Background The role of B cells in anti-tumor immunity remains controversial, with studies suggesting the pro-tumor and anti-tumor activity. This controversy may be due to the heterogeneity in B cell populations, as the balance among the subtypes may impact tumor progression. The immunosuppressive regulatory B cells (Breg) release IL-10 but only represent a minor population. Additionally, tumor-specific antibodies (Ab) also exhibit anti-tumor and pro-tumor function dependent on the Ab isotype. Transcription factor c-Maf has been suggested to contribute to the regulation of IL-10 in Breg, but the role of B cell c-Maf signaling in anti-tumor immunity and regulating antibody responses remain unknown. Methods Conditional B cell c-Maf knockout (KO) and control mice were used to establish a KPC pancreatic cancer model and B16.F10 melanoma model. Tumor progression was evaluated. B cell and T cell phenotypes were determined by flow cytometry, mass cytometry, and cytokine/chemokine profiling. Differentially expressed genes in B cells were examined by using RNA-seq. Peripheral blood samples were collected from healthy donors and melanoma patients for B cell phenotyping. Results Compared to B cells from spleen and lymph nodes, B cells in the pancreas exhibited significantly less follicular phenotype and higher IL-10 production in tumor-free mice. c-Maf deficiency resulted in a significant reduction of CD9+ IL-10-producing Breg in the pancreas. PDAC progression resulted in accumulation of circulating B cells with follicular phenotype and less IL-10 production in the pancreas. Notably, B cell c-Maf deficiency delayed PDAC tumor progression and resulted in pro-inflammatory B cells. Further, tumor volume reduction and increased effective T cells in the tumor-draining lymph node (TDLN) were observed in B cell c-Maf KO mice in the B16.F10 melanoma model. RNA-seq analysis of isolated B cells revealed that B cell c-Maf signaling modulates immunoglobulin (Ig)-associated genes and tumor specific antibody production. We furthermore demonstrated c-Maf-positive B cell subsets and increase of IL-10-producing B cells after incubation with IL-4 and CD40L in the peripheral blood of melanoma patients. Conclusion Our study highlights that B cell c-Maf signaling drives tumor progression through the modulation of Breg, inflammatory responses, and tumor-specific Ab responses.

Transcription Factor C-Maf-targeted Cancer Immunotherapy.

Transcription Factor C-Maf is a Checkpoint That Programs Macrophages in Lung Cancer.

Targeting the Oncogenic Transcription Factor C-Maf for the Treatment of Multiple Myeloma.

c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes

[Progress on Cancer Associated Fibroblasts in Tumor Immunoregulation].

c-Maf controls immune responses by regulating disease-specific gene networks and repressing IL-2 in CD4+ T cells

A new MAFia in cancer

CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Cancer-associated Fibroblasts: Just on the Opposite Side of Antitumour Immunity?

Activation of the Transcription Factor C-Maf in T Cells is Dependent on the CARMA1-IKKβ Signaling Cascade

The Immunomodulatory Role of the MAFB Gene in Hepatocellular Carcinoma and Its Impact on Biological Activities.

Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

The role and regulation of Maf proteins in cancer

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy

B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma

Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution

CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage

Differential metabolic requirement governed by transcription factor c-Maf dictates innate γδT17 effector functionality in mice and humans